150 related articles for article (PubMed ID: 17519149)
21. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive.
Paiva LC; Pinto-Neto AM; Faundes A
Contraception; 1998 Dec; 58(6):351-5. PubMed ID: 10095971
[TBL] [Abstract][Full Text] [Related]
22. Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives.
Bahamondes L; Juliato CT; Villarreal M; Sobreira-Lima B; Simões JA; dos Santos Fernandes AM
Contraception; 2006 Sep; 74(3):259-63. PubMed ID: 16904421
[TBL] [Abstract][Full Text] [Related]
23. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report.
Contraception; 1983 Jul; 28(1):1-20. PubMed ID: 6226488
[TBL] [Abstract][Full Text] [Related]
24. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections.
Harel Z; Johnson CC; Gold MA; Cromer B; Peterson E; Burkman R; Stager M; Brown R; Bruner A; Coupey S; Hertweck P; Bone H; Wolter K; Nelson A; Marshall S; Bachrach LK
Contraception; 2010 Apr; 81(4):281-91. PubMed ID: 20227543
[TBL] [Abstract][Full Text] [Related]
25. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study.
Pongsatha S; Ekmahachai M; Chaovisitsaree S; Suntornlimsiri N; Morakote N
J Med Assoc Thai; 2009 Oct; 92(10):1263-7. PubMed ID: 19845231
[TBL] [Abstract][Full Text] [Related]
26. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health.
Petitti DB; Piaggio G; Mehta S; Cravioto MC; Meirik O
Obstet Gynecol; 2000 May; 95(5):736-44. PubMed ID: 10775740
[TBL] [Abstract][Full Text] [Related]
27. Effect of depot medroxyprogesterone acetate on bone mineral density in adolescent women.
Zhang MH; Zhang W; Zhang AD; Yang Y; Gai L
Chin Med J (Engl); 2013 Nov; 126(21):4043-7. PubMed ID: 24229671
[TBL] [Abstract][Full Text] [Related]
28. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate.
Perrotti M; Bahamondes L; Petta C; Castro S
Fertil Steril; 2001 Sep; 76(3):469-73. PubMed ID: 11532466
[TBL] [Abstract][Full Text] [Related]
29. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls.
Cromer BA; Stager M; Bonny A; Lazebnik R; Rome E; Ziegler J; Debanne SM
J Adolesc Health; 2004 Dec; 35(6):434-41. PubMed ID: 15581522
[TBL] [Abstract][Full Text] [Related]
30. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
[TBL] [Abstract][Full Text] [Related]
31. [Status of bone mineral density after the long-standing application of contraception Depo-Provera].
Zeman S; Havlík P; Zemanová J; Němec D
Ceska Gynekol; 2013 Jan; 78(1):116-24. PubMed ID: 23607391
[TBL] [Abstract][Full Text] [Related]
32. Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact of the boxed warning.
Eworuke E; Popat V; Moeny DG
J Clin Pharm Ther; 2017 Aug; 42(4):483-494. PubMed ID: 28543135
[TBL] [Abstract][Full Text] [Related]
33. Effects of hormonal contraception on bone mineral density after 24 months of use.
Berenson AB; Breitkopf CR; Grady JJ; Rickert VI; Thomas A
Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563
[TBL] [Abstract][Full Text] [Related]
34. Long-acting hormonal contraceptives for women.
Garza-Flores J; Hall PE; Perez-Palacios G
J Steroid Biochem Mol Biol; 1991; 40(4-6):697-704. PubMed ID: 1958567
[TBL] [Abstract][Full Text] [Related]
35. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.
Draper BH; Morroni C; Hoffman M; Smit J; Beksinska M; Hapgood J; Van der Merwe L
Cochrane Database Syst Rev; 2006 Jul; (3):CD005214. PubMed ID: 16856087
[TBL] [Abstract][Full Text] [Related]
36. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.
Viola AS; Castro S; Marchi NM; Bahamondes MV; Viola CF; Bahamondes L
Contraception; 2011 Aug; 84(2):122-7. PubMed ID: 21757052
[TBL] [Abstract][Full Text] [Related]
37. Bone mineral density and depot medroxyprogesterone acetate.
Albertazzi P; Bottazzi M; Steel SA
Contraception; 2006 Jun; 73(6):577-83. PubMed ID: 16730487
[TBL] [Abstract][Full Text] [Related]
38. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa.
Myer L; Denny L; Wright TC; Kuhn L
Int J Epidemiol; 2007 Feb; 36(1):166-74. PubMed ID: 17175547
[TBL] [Abstract][Full Text] [Related]
39. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
[TBL] [Abstract][Full Text] [Related]
40. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
